RxDoctor Payments DataLook up a doctor →

Wesley Brookover, MD

Urology · Tulsa, OKNPI 1659457455

Payments from drug & device makers

$12,972in general payments, 2019–2025

Across 560 payments — averaging $23.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Astellas Pharma US Inc$1K
  • Dendreon Pharmaceuticals LLC$1K
  • Pfizer$774
  • Urogen Pharma, Inc.$681
  • Coloplast$618
  • plus $7K from 43 others

What the payments were for

  • Food & beverage$12,42696%
  • Education$5464%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,972 in reported general payments places this provider in the 85th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$441,419
Medicare patients
1,107
Services billed
20,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide18$264,903
MyrbetriqMirabegron132$94,304
GemtesaVibegron70$49,134
Abiraterone Acetate27$39,917
Tamsulosin Hcl1,564$17,634
Finasteride1,232$17,122
Doxycycline Hyclate190$3,096
Tolterodine Tartrate ErTolterodine Tartrate30$3,086
Alfuzosin Hcl ErAlfuzosin Hcl136$3,048
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst93$2,474
Potassium Citrate ErPotassium Citrate41$2,027
Dutasteride51$1,828
Testosterone Cypionate57$1,639
Doxazosin Mesylate90$1,396
Fesoterodine Fumarate ErFesoterodine Fumarate11$1,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,843$264,90318 claims
Astellas Pharma US IncMyrbetriq$1,489$94,304132 claims
Sumitomo Pharma America, Inc.Gemtesa$343$49,13470 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 145 urology providers in Oklahoma.

Other urology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →